A Multicenter Clinical Trial Evaluating the Efficacy and Safety of Taurine as an Adjunctive Therapy in Multiple Sclerosis

• Status: NOT_YET_RECRUITING
• Trial end date: 2029-11-01

Summary

This multicenter, randomized, open-label clinical trial aims to evaluate the efficacy and safety of taurine as an adjunctive therapy to standard disease-modifying treatments (DMTs) in patients with multiple sclerosis (MS). The study seeks to determine whether oral taurine can reduce the number and volume of new or enlarging MRI lesions, decrease relapse rates, and slow disability progression as measured by the Expanded Disability Status Scale (EDSS). It will also explore the effects of taurine on gut microbiota composition, serum neurodegeneration biomarkers (GFAP and NfL), and cognitive function assessed by MMSE and MoCA. Approximately 80 eligible participants will be enrolled and randomly assigned to either continue standard DMT therapy or receive taurine supplementation in addition to DMTs. The treatment duration will be 24 months, with follow-up visits every 3 months for clinical assessment, blood and stool sample collection, and MRI scans every 6 months. This study aims to provide new clinical evidence supporting taurine as a safe and potentially beneficial adjunctive therapy for multiple sclerosis.

• Phase: PHASE2

Details

• Lead Sponsor: Sichuan Academy of Medical Sciences
• Collaborators: Afliated Hospital of North Sichuan Medical College; Beijing Tiantan Hospital; Daping Hospital of Army Medical University; First Affiliated Hospital of Chongqing Medical University; First Affiliated Hospital of Kunming Medical University; Lanzhou University Second Hospital; Shandong Provincial Hospital; Tang-Du Hospital; The Affiliated Hospital of Inner Mongolia Medical University; The First Affiliated Hospital of Hainan Medical College; The People's Hospital of Leshan
• Treatments: Taurine